# Quality Assurance Report

---

# Identity

| Field | Value |
|-------|-------|
| QA Report ID | QA-PP-0147 |
| Population Package | PP-0147 |
| Version | 1.0.0 |
| Review Status | PASS |

---

# Layer 1 — Content QA

| Criterion | Result |
|-----------|--------|
| Single educational question | PASS |
| Scope respected | PASS |
| Complete coverage | PASS |
| Internal consistency | PASS |
| Logical organization | PASS |
| Knowledge blocks complete | PASS |
| No overlap with adjacent Population Packages | PASS |
| Atomic Knowledge Principle preserved | PASS |

---

# Layer 2 — Clinical QA

| Criterion | Result |
|-----------|--------|
| Scientifically accurate | PASS |
| Consistent with ACMG | PASS |
| Consistent with AMP | PASS |
| Consistent with ClinGen SVI | PASS |
| Disease-specific implementation appropriately represented | PASS |
| Appropriate explanation of BS3 | PASS |
| Appropriate explanation of functional evidence | PASS |
| Disease mechanism appropriately emphasized | PASS |
| Assay applicability appropriately emphasized | PASS |
| Assay validity appropriately emphasized | PASS |
| Controls appropriately addressed | PASS |
| Reproducibility appropriately addressed | PASS |
| BS3 versus PS3 distinction accurate | PASS |
| No universal assay rule implied | PASS |
| No unsupported clinical claim | PASS |
| No unsafe medical advice | PASS |

---

# Layer 3 — Educational QA

| Criterion | Result |
|-----------|--------|
| Plain language | PASS |
| Appropriate for gastric-cancer patients and caregivers | PASS |
| Learning objectives satisfied | PASS |
| Common misconceptions addressed | PASS |
| "Normal result = benign" misconception corrected | PASS |
| Functional-study concept explained | PASS |
| Disease relevance explained | PASS |
| Controls explained | PASS |
| Reproducibility explained | PASS |
| Technical implementation appropriately deferred | PASS |

---

# Layer 4 — Governance QA

| Criterion | Result |
|-----------|--------|
| CKO completed | PASS |
| Knowledge Passport completed | PASS |
| Evidence Package completed | PASS |
| Evidence traceability complete | PASS |
| Scope maintained | PASS |
| Knowledge Graph complete | PASS |
| Gastric-cancer context preserved | PASS |
| Versioning complete | PASS |
| Repository compliant | PASS |
| Disease-specific implementation boundary encoded | PASS |

---

# Clinical Safety Review

| Item | Result |
|------|--------|
| No unsafe medical advice | PASS |
| No automatic benign classification implied | PASS |
| No "normal assay = BS3" shortcut | PASS |
| Disease mechanism emphasized | PASS |
| Assay relevance emphasized | PASS |
| Assay validity emphasized | PASS |
| Appropriate controls emphasized | PASS |
| Reproducibility emphasized | PASS |
| Disease-specific VCEP implementation acknowledged | PASS |
| Gastric-cancer context preserved | PASS |
| No treatment recommendations | PASS |

---

# Educational Boundary Review

The Population Package remains within the predefined educational boundary.

### Included

- BS3 definition
- Functional studies
- No-damaging-effect principle
- Meaning of well-established
- Assay validity
- Controls
- Reproducibility
- Disease relevance
- PS3 versus BS3
- Gastric-cancer context
- Patient implications

### Excluded

- Detailed assay protocols
- Laboratory validation procedures
- Statistical calibration
- OddsPath
- Detailed ClinGen SVI algorithm
- Gene-specific VCEP specifications
- BS3_Moderate / BS3_Supporting
- PS3 implementation
- Detailed RNA-splicing implementation
- Bayesian framework
- ACMG evidence combination
- Laboratory workflow
- Treatment recommendations

The **Atomic Knowledge Principle** has been fully preserved.

---

# Runtime Safety Review

The package establishes the following safety boundary:

> **A normal functional assay result does not automatically establish BS3 or a benign final classification.**

The Safe Medical AI System must avoid statements such as:

- "The laboratory experiment was normal, so the variant is benign."
- "Any functional study can be used for BS3."
- "A functional assay validated for one gene automatically applies to another gene."
- "BS3 alone proves that a variant cannot cause gastric cancer."

Instead, the system should communicate that BS3 depends on:

- disease mechanism;
- assay applicability;
- assay validity;
- controls;
- reproducibility;
- variant-level interpretation;
- and applicable disease-specific guidance.

---

# Final Quality Decision

## PASS

PP-0147 satisfies the locked **Gold Population Package Specification v1.0**.

Approved as the official Population Package for:

> **PP-0147 — BS3 (Well-Established Functional Studies Show No Deleterious Effect on Gene or Gene Product)**

---

# Reviewer Notes

This Population Package preserves the key distinction between:

**a normal experimental result**

and

**well-established, disease-relevant functional evidence supporting no damaging effect**.

This distinction is essential because ClinGen SVI developed a structured PS3/BS3 framework precisely to improve consistency in functional-evidence interpretation.

For the gastric-cancer system, the package also preserves the requirement that functional evidence be interpreted in the context of the **specific gene, disease mechanism, and hereditary gastric-cancer context**, without broadening the Atomic Knowledge scope.

The package maintains strict adherence to the **Atomic Knowledge Principle** and the locked **Gold Workflow**.